The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded an increase of 27.25%. However, over the last six months, the performance has been weaker by 121.29%. The price of PBYI increased 6.37% over the last 30 days. And in the last five days, it has fallen by -1.25%.
In terms of market performance, Puma Biotechnology Inc had a somewhat regular. The highest value for the stock in the past year was $7.73 on 02/15/24, while the lowest value was $2.13 on 10/25/23.
52-week price history of PBYI Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Puma Biotechnology Inc’s current trading price is -28.72% away from its 52-week high, while its distance from the 52-week low is 158.69%. The stock’s price range over this timeframe has been between $2.13 and $7.73. The shares of the Healthcare sector company recorded a trading volume of approximately 0.53 million for the day, which was comparatively lower than the average daily volume of 0.62 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Puma Biotechnology Inc (PBYI) has experienced a quarterly rise of 25.51% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 265.64M and boasts a workforce of 185 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.89, with a change in price of +2.35. Similarly, Puma Biotechnology Inc recorded 509,405 in trading volume during the last 100 days, posting a change of +74.37%.
PBYI’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for PBYI stands at 2.09. Similarly, the long-term debt-to-equity ratio is also 1.36.
PBYI Stock Stochastic Average
The raw stochastic average for Puma Biotechnology Inc over the last 50 days is presently at 38.16%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 78.29%. Further, the company’s Stochastic %K and %D values for the last 20 days were 70.86% and 66.76%, respectively.
